A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study

Investigational New Drugs

Volumn 21, Issue 4, 2003, Pages 453-457

  Armstrong, Deborah K ^a   Blessing, John A ^b   Rader, Janet ^c   Sorosky, Joel I ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Advanced cervical cancer; Bryostatin 1; Protein kinase C (PKC)

Indexed keywords

BRYOSTATIN 1; NSC 339555;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MYALGIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANEMIA; CARCINOMA, SQUAMOUS CELL; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTONES; MACROLIDES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; UTERINE CERVICAL NEOPLASMS;

EID: 1642452915     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026255403046     Document Type: Article

References (15)

1. Stehman FB, Perez CA, Jurman RJ, Thigpen JT: Uterine cervix. In: Hoskins WJ, Perez CA, and Young RC (eds) Principles and Practice of Gynecologic Oncology, 2nd edn. Lippincott-Raven, Philadelphia, PA, 1997, pp. 785-857
2. Rose PG, Eifel PJ: Combined radiation therapy and chemotherapy for carcinoma of the cervix. Cancer 7(2): 86-94, 2001
3. Penalver MA, Barreau G, Sevin BU, Averatee HE: Surgery for the treatment of locally recurrent disease. J Natl Cancer Inst Monogr 21: 117-122, 1996
4. Omura GA: Chemotherapy for cervical cancer. Sem Oncol 21(1): 54-62, 1994
5. Thigpen T, Shingleton A, Homesley H, Lagasse L, Blessing J: Cisplatinum in the treatment of advanced or recurrent squamous carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group. Cancer 48(4): 899-903, 1981
6. Thigpen T, Vance R, Khansur T, Malamud F: The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix. Sem Oncol 23(3,6): 46-64, 1996
7. Thigpen T, Vance R, Khansur T, Malamud F: The role of paclitaxel in the management of patients with carcinoma of the cervix. J Sem Oncol 24(1,2): 41-46, 1997
8. Kumar L, Pokharel YH, Kumar S, Singh R, Rath GK, Kochupillai V: Single agent versus combination chemotherapy in recurrent cervical cancer. J Obstet Gynecol Res 24(6): 401-409, 1998
9. Pettit GR, Herald CL, Doubek DL, Herald D: Isolation and structure of bryostatin-1. J Am Chem Soc 104: 6846-6848, 1982
10. Mutter R, Wills M: Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 8(8): 1841-1860, 2000
11. Philip PA, Zonder JA: Pharmacology and clinical experience with bryostatin-1: a novel anticancer drug. Expert Opin Investig Drugs 8(12): 2189-2199, 1999
12. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M: A phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 68(2): 418-424, 1993
13. O'Reilly S, Slichenmyer W, Hess A, Donehower R: A phase I and immunologic study of bryostatin-2 in patients with solid tumors. Proc Amer Assoc Cancer Res 56: 802-808, 1996
14. Hickman PF, Kemp GJ, Thompson CH, Salisbury AJ, Wade K, Harris AL, Radda GK: Bryostatin-1, a novel anti-neoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br J Cancer 72(4): 998-1003, 1995
15. Basu A, Lazo JS: Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum (II) by bryostatin-1. Cancer Res 52(11): 3119-3124, 1992